AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01638767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Contraceptives, Oral
Description: 0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.
Study NCT01638767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contraceptive, Vaginal ring
Description: etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day
Study NCT02947555 — intervention group
Intervention type: OTHER
Intervention: Non interventional
Study NCT00096122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT01947686 — intervention group
Intervention type: DEVICE
Intervention: Robotically guided patellofemoral UKA isolated patellofemoral implants
Description: A robot guided isolated patellofemoral unicompartmental knee arthroplasty procedures to replace only the patellofemoral component of the knee.
Study NCT01463982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oratecan and Capecitabine
Description: Oratecan in combination with Capecitabine~* Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1\~Day5~* HM30181AK Tablet - Fixed dose 15 mg, Day1\~Day5~* Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1\~Day14
Study NCT01139606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration resistance training
Description: adding vibration to a standard resistance training with free-weights and checking the effect on muscle strength development and everyday functioning of upper limbs in untrained adults.
Study NCT04601350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam group was induced with remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia
Description: remimazolam group was remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia
Study NCT02505178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: PST is a minimally invasive treatment. The five sessions of CM implemented PST will involve psychotherapy also known as talk therapy between the CM's and study participants in a group setting. Psychogeriatric interdisciplinary staff (CM's) i.e. psychiatric nurses, social workers who have been previously trained in PST will function in the roles of facilitator, cofacilitator and scribe. The roles can be shared amongst the professionals to build capacity in each role or maintained over time if so desired. Sessions will be approximately one-and-a-half to two hours in length and conducted at the Cherry Hill Mall library in London.
Study NCT03529812 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBCT-informed training
Description: Cognitively-Based Compassion Training (CBCT) is a secularized compassion meditation program adapted from the Tibetan Buddhist mind training (lojong) tradition. Lojong practices utilize a cognitive, analytic approach to challenge one's unexamined thoughts and emotions toward other people, with the long-term goal of developing altruistic emotions and behavior towards all people.
Study NCT03529812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT-informed training
Description: Cognitively-Based Compassion Training (CBCT) is a secularized compassion meditation program adapted from the Tibetan Buddhist mind training (lojong) tradition. Lojong practices utilize a cognitive, analytic approach to challenge one's unexamined thoughts and emotions toward other people, with the long-term goal of developing altruistic emotions and behavior towards all people.
Study NCT03437512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: 20 minutes of 2mA anodal stimulation.
Study NCT03437512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluency training
Description: Speaking along with a metronome and/or speaking along with another person (choral speech) for 20 minutes
Study NCT03437512 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Fluency training
Description: Speaking along with a metronome and/or speaking along with another person (choral speech) for 20 minutes
Study NCT03437512 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: For sham stimulation, current is ramped up and back down over 30 seconds.
Study NCT02247531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: 10 mg dose of lampalizumab administered intravitreally.
Study NCT02247531 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
Study NCT01423019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Advantra Z
Description: Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine.
Study NCT01423019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Advantra Z + Naringin + Hesperiden
Description: Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine, 600 mg naringin, and 100 mg hesperiden.
Study NCT04601350 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1
Description: control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1
Study NCT04095624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinal Fusion Preoperative Opioid Taper
Description: Guided weekly opioid pain medication reduction via telephone calls prior to elective spinal fusion surgery.
Study NCT04095624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-taper Control
Description: Weekly phone calls prior to elective spinal fusion surgery, without opioid pain medication reduction recommendation or guidance.
Study NCT00464113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL228
Description: 1-hour IV infusion
Study NCT02875028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: 10mg-20mg vorapaxar to achieve >80% thrombin-receptor activated peptide-6 (TRAP) induced platelet inhibition
Study NCT02875028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02875028 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LPS
Description: 2ng/kg Lipopolysaccharide as a bolus infusion
Study NCT02875028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPS
Description: 2ng/kg Lipopolysaccharide as a bolus infusion
Study NCT00959569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: esmolol (1-3 mg/kg) during cardiac surgery
Study NCT00959569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normosaline (same ml of the study drug)
Study NCT04983524 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: propolis
Description: resinous product of honeybees
Study NCT04983524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: Gold standard control intracanal medicament
Study NCT03095755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning
Description: Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
Study NCT03095755 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
Study NCT01423019 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Two capsules containing inert ingredients are taken twice daily, 20-30 minutes before breakfast and evening meals.
Study NCT02078726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: glucagon (hormone produced by the body)
Study NCT02078726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon
Description: glucagon (hormone produced by the body)
Study NCT02500836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine HCl 4% Topical Solution
Description: Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
Study NCT02500836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine HCl 10% Topical Solution
Description: Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
Study NCT02500836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Solution
Description: Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
Study NCT03594474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion
Description: using higher dose of IV lipids after birth
Study NCT01145183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
Study NCT01145183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo daily dosing
Study NCT02208167 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HXTC infusion
Study NCT04164719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them
Study NCT01891110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ES of the abdominal muscles
Description: ES was applied with surface electrodes and fixed stimulation parameters with individual mA, depending on each patients´ sensibility.
Study NCT01891110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ES of the limb muscles
Description: Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
Study NCT01891110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ES of limbs & abdomen
Description: The combination of the ES of the lower limb muscles and the abdominal muscles.
Study NCT04357470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand Therapy
Description: The patients were admitted to 12-weeks rehabilitation program and were called up once a week for follow-up appointments. Hand therapy continued as home program between 12th week and 6th month.
Study NCT02855073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ReJoinTM
Description: adipose derived mesenchymal progeinitor cells
Study NCT02855073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium Hyaluronate Injection
Study NCT03637023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality Based Rehabilitation including static balance, dynamic balance and walking
Study NCT03637023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: The conventional physical Therapy program includes parameters for improving strength, flexibility, transfers, posture, balance and coordination, and sensory stimulation. These activities consist of various types of exercises that focus on lower extremity movements.
Study NCT03084731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiota Directed Complementary Food (MDCF)
Description: For Study 1: Investigators will test 3 prototype MDCFs and the current RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 2: From study 1 Investigators will select most efficacious MDCF and compare with 2 additional MDCF prototypes to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 3: Investigators will select the lead MDCF from study 2 and examine the effects between the final MDCF versus current RUSF and also examine the impact dispensing of the lead MDCF once versus twice per day with a 4 week post-intervention period.
Study NCT02801578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Cycle 1 daily dose of ibrutinib is 420 mg (3 capsules), in the second cycle 280 mg (2 capsules), and in the third cycle 140 mg (1 capsule).
Study NCT02923167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted training of the hand
Description: Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant's fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
Study NCT00829465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licartin
Description: Licartin
Study NCT00829465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter arterial chemoembolization
Description: TACE
Study NCT00829465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization
Description: TACE
Study NCT03412591 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Suvorexant 20 mg
Description: Suvorexant 20 mg is an orexin 1/2receptor antagonist approved for the treatment of sleep disturbance in subjects with Primary Insomnia.
Study NCT05460286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Manipulation
Description: 20 participants with low back pain existing more than 3 months was included in the CSMT group. Lumbar region chiropractic HVLA (High Velocity, Low Amplitude) spinal manipulation and/or sacroiliac joint chiropractic HVLA manipulation were applied to participants. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
Study NCT05460286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Decompression Device Treatment
Description: 20 participants with low back pain existing more than 3 months was included in the SD group. Lumbar region spinal decompression (traction) device therapy was applied to participants, and as a standard of treatment was given a hot pack for 15 minutes before applying and a cold pack for 10 minutes after applying. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
Study NCT02108808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Study NCT02108808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel or Clopidogrel
Study NCT03590548 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: gausher disease
Description: lab investigation and radio logical
Study NCT01484756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: daily multi micronutrient supplement
Description: Multi micro-nutrient supplement tablet containing 40 mg elemental zinc (as gluconate, 120 mg ascorbic acid, 6 mg beta-carotene, 15 mg alpha-tocopherol (as d-alpha-tocopheryl acid succinate, 400 micrograms folic acid in experimental group given daily for six months
Study NCT01484756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: calcium carbonate 500 mg
Study NCT05115773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraligamentary anaesthesia
Description: one tooth anaesthesia by 2 or 4 points intraligamentary injection
Study NCT05115773 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular anaesthesia
Description: Inferior alveolar nerve block by direct standart method
Study NCT03601078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb2121
Description: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
Study NCT01266980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled FF/ GW642444M (200/25mcg)
Description: All subjects will be assigned to take FF/ GW642444M (200/25mcg) combination once daily for 7 days.
Study NCT04722393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise training
Study NCT02429427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
Study NCT02136992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
Study NCT03601078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalomide
Description: Specified dose on specified days
Study NCT03601078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Specified dose on specified days
Study NCT03061097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous fecal microbiota transplant (Auto-FMP Enema)
Description: FMT is the process by which processed donor microbiota material is transplanted into recipients. The aim is to reconstitute the normal intestinal microbial flora in recipients. In this study, the fecal microbiota preparation will be made from the participant's own stool and processed into an auto-FMP enema formulation.
Study NCT03061097 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Enema Preparation
Description: The placebo enema preparation will be identical in appearance but will not contain human feces to prevent unmasking of the trial arms.
Study NCT00610623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin
Description: 300 mg/day, IV from day 1 to 20
Study NCT00610623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once per day, IV from day 1 to 20
Study NCT00958789 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon TS Knee System
Description: Total knee replacement for revision cases
Study NCT04233463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modulen
Description: Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
Study NCT04678128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance4Healing Telehealth Live Zoom Sessions
Description: Week 1: 2-hour introduction session on Zoom platform with a live dance instructor at the participant's desired level of activity intensity (low, mild, or moderate).~Weeks 2-8: All participants will be asked to participate in a 1 hour online, instructor-led live class.
Study NCT04678128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dance4Healing Telehealth Live Zoom Sessions
Description: Week 1: 2-hour introduction session on Zoom platform with a live dance instructor at the participant's desired level of activity intensity (low, mild, or moderate).~Weeks 2-8: All participants will be asked to participate in a 1 hour online, instructor-led live class.
Study NCT02136992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
Study NCT04678128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Buddy
Description: Following randomization (beginning of intervention period) half of the participants will be assigned a dance buddy, and will be asked to dance with their buddies using the Dance4Healing TLVP at least 2 additional times/week. This group will have 24/7 access to Dance4Healing Platform during the intervention and post-intervention periods.